Quantum Financial Advisors LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Quantum Financial Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 153.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,601 shares of the company's stock after buying an additional 3,387 shares during the quarter. Quantum Financial Advisors LLC's holdings in Johnson & Johnson were worth $929,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Tallon Kerry Patrick bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $290,000. Capital & Planning LLC raised its holdings in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after acquiring an additional 183 shares in the last quarter. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $85,886,000. Finally, Curbstone Financial Management Corp raised its holdings in shares of Johnson & Johnson by 1.1% during the fourth quarter. Curbstone Financial Management Corp now owns 26,732 shares of the company's stock valued at $3,866,000 after acquiring an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.1%

Shares of JNJ traded up $0.16 during trading hours on Monday, hitting $155.37. The company had a trading volume of 6,665,172 shares, compared to its average volume of 7,943,546. The company has a market capitalization of $373.83 billion, a PE ratio of 23.36, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company's fifty day moving average price is $154.31 and its two-hundred day moving average price is $153.66.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.35%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Raymond James dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.